We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases. Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic. Source
No articles found.
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
SelenBio, Inc is a biotechnology company specializing in the prevention of bacteri...
SelenBio, Inc is a biotechnology company specia...
Kare is the new mobile dental platform on the market for concierge style dental tr...
Kare is the new mobile dental platform on the m...
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the li...
SCYNEXIS, Inc. is a biotechnology company commi...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, Calif., is the...
Intuitive Surgical, Inc. (Nasdaq:ISRG), headqua...
Join the National Investor Network and get the latest information with your interests in mind.